Cargando…

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

CRISPR/Cas9 technology offers novel approaches for the development of new therapies for many unmet clinical needs, including a significant number of inherited monogenic diseases. However, in vivo correction of disease-causing genes is still inefficient, especially for those diseases without selectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zabaleta, Nerea, Barberia, Miren, Martin-Higueras, Cristina, Zapata-Linares, Natalia, Betancor, Isabel, Rodriguez, Saray, Martinez-Turrillas, Rebeca, Torella, Laura, Vales, Africa, Olagüe, Cristina, Vilas-Zornoza, Amaia, Castro-Labrador, Laura, Lara-Astiaso, David, Prosper, Felipe, Salido, Eduardo, Gonzalez-Aseguinolaza, Gloria, Rodriguez-Madoz, Juan R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303323/ https://www.ncbi.nlm.nih.gov/pubmed/30575740 http://dx.doi.org/10.1038/s41467-018-07827-1

Ejemplares similares

In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria
por: Martinez-Turrillas, Rebeca, et al.
Publicado: (2022)

Improving Treatment Options for Primary Hyperoxaluria
por: Hoppe, Bernd, et al.
Publicado: (2022)

Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias
por: Moya-Garzon, Maria Dolores, et al.
Publicado: (2021)

mRNA and gene editing: Late breaking therapies in liver diseases
por: Zabaleta, Nerea, et al.
Publicado: (2022)

Is stiripentol truly effective for treating primary hyperoxaluria?
por: Martin-Higueras, Cristina, et al.
Publicado: (2020)

Diet-related urine collections: assistance in categorization of hyperoxaluria
por: Dill, Hannah, et al.
Publicado: (2021)

Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure
por: Scala, Marianna Di, et al.
Publicado: (2016)

AAV-HDV: An Attractive Platform for the In Vivo Study of HDV Biology and the Mechanism of Disease Pathogenesis (†)
por: Maestro, Sheila, et al.
Publicado: (2021)

IL12-Mediated Liver Inflammation Reduces the Formation of AAV Transcriptionally Active Forms but Has No Effect over Preexisting AAV Transgene Expression
por: Gil-Fariña, Irene, et al.
Publicado: (2013)

TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection
por: Usai, Carla, et al.
Publicado: (2020)

Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium
por: Metry, Elisabeth L., et al.
Publicado: (2023)

Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome
por: Rodriguez-Madoz, Juan Roberto, et al.
Publicado: (2017)

Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria
por: Lai, Chengjung, et al.
Publicado: (2018)

Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice
por: Di Scala, Marianna, et al.
Publicado: (2016)

Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I
por: Recker, Pia, et al.
Publicado: (2022)

Simple, fast and inexpensive quantification of glycolate in the urine of patients with primary hyperoxaluria type 1
por: Boehm, Thomas, et al.
Publicado: (2023)

The Role of Protein Denaturation Energetics and Molecular Chaperones in the Aggregation and Mistargeting of Mutants Causing Primary Hyperoxaluria Type I
por: Mesa-Torres, Noel, et al.
Publicado: (2013)

Primary Hyperoxaluria
por: Harambat, Jérôme, et al.
Publicado: (2011)

Protein Homeostasis Defects of Alanine-Glyoxylate Aminotransferase: New Therapeutic Strategies in Primary Hyperoxaluria Type I
por: Pey, Angel L., et al.
Publicado: (2013)

Hyperoxaluria Induces Endothelial Dysfunction in Preglomerular Arteries: Involvement of Oxidative Stress
por: Saenz-Medina, Javier, et al.
Publicado: (2022)

Novel vectors and approaches for gene therapy in liver diseases
por: Maestro, Sheila, et al.
Publicado: (2021)

Danio Rerio as Model Organism for Adenoviral Vector Evaluation
por: Gulías, Paola, et al.
Publicado: (2019)

Primary hyperoxaluria and systemic oxalosis
por: Sriram, K., et al.
Publicado: (2007)

Enteric hyperoxaluria in chronic pancreatitis
por: Demoulin, Nathalie, et al.
Publicado: (2017)

Molecular Recognition of PTS-1 Cargo Proteins by Pex5p: Implications for Protein Mistargeting in Primary Hyperoxaluria
por: Mesa-Torres, Noel, et al.
Publicado: (2015)

Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD)
por: Saenz-Pipaon, Goren, et al.
Publicado: (2020)

Pancytopenia as a Complication of Primary Hyperoxaluria
por: Khosravi, M., et al.
Publicado: (2019)

The Struggling Odyssey of Infantile Primary Hyperoxaluria
por: Guillaume, Adrien, et al.
Publicado: (2021)

Treatment of primary hyperoxaluria type 1
por: Gupta, Asheeta, et al.
Publicado: (2022)

Primary hyperoxaluria: a case series
por: Rather, Jawad Iqbal, et al.
Publicado: (2023)

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
por: Rodriguez-Marquez, Paula, et al.
Publicado: (2022)

Revealing cell populations catching the early stages of human embryo development in naive pluripotent stem cell cultures
por: Moya-Jódar, Marta, et al.
Publicado: (2022)

One-Step In Vitro Generation of ETV2-Null Pig Embryos
por: Moya-Jódar, Marta, et al.
Publicado: (2022)

In Vitro and In Vivo Genetic Disease Modeling via NHEJ-Precise Deletions Using CRISPR-Cas9
por: López-Manzaneda, Sergio, et al.
Publicado: (2020)

Heme oxygenase-1 inducer hemin does not inhibit SARS-CoV-2 virus infection
por: Maestro, Sheila, et al.
Publicado: (2021)

Bilateral nephrocalcinosis in primary hyperoxaluria type 1
por: Mansoor, C. A., et al.
Publicado: (2016)

Primary Hyperoxaluria Involving the Liver With Crystal Deposits
por: Bansal, Nalini, et al.
Publicado: (2019)

ALLN-177, oral enzyme therapy for hyperoxaluria
por: Lingeman, James E., et al.
Publicado: (2019)

Primary hyperoxaluria type 1: pathophysiology and genetics
por: Fargue, Sonia, et al.
Publicado: (2022)

Primary hyperoxaluria: the pediatric nephrologist's point of view
por: Ben-Shalom, Efrat, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o9v30av4h2lkvjslkdm5tnoi7h